Skip to Content
You are currently on the new version of our website. Access the old version .
AntibodiesAntibodies
  • Editor’s Choice
  • Review
  • Open Access

11 January 2023

16 Pages

A Review of the Currently Available Antibody Therapy for the Treatment of Coronavirus Disease 2019 (COVID-19)

and
1
Gyeongsang Institute of Health Sciences, Gyeongsang National University, Jinju 52727, Republic of Korea
2
Major of Food Science & Nutrition, Pukyong National University, Busan 48513, Republic of Korea
*
Author to whom correspondence should be addressed.

Abstract

Monoclonal antibodies are a promising treatment for COVID-19. However, the emergence of SARS-CoV-2 variants raised concerns about these therapies’ efficacy and long-term viability. Studies reported several antibodies, that received authorization for COVID-19 treatment, are not effective against new variants or subvariants of SARS-CoV-2, hence their distribution has to be paused. Here, the authors reviewed the status of the currently available monoclonal antibodies for COVID-19 treatment, their potential as a therapeutic agent, and the challenges ahead. To address these issues, the authors presented general information on SARS-CoV-2 and how monoclonal antibodies work against SARS-CoV-2. The authors then focus on the antibodies that have been deployed for COVID-19 treatment and their current status, as well as the evidence supporting their potential as an early intervention against COVID-19. Lastly, the authors discussed some leading obstacles that hinder the development and administration of monoclonal antibodies for the treatment of COVID-19.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.